Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

ZenaTech fortalece las capacidades de Drone como Servicio para los mercados gubernamentales y de aviación con el cierre de la adquisición de Smith Surveying Group en Jacksonville, Florida

View original at globenewswire.com
ZenaTech fortalece las capacidades de Drone como Servicio para los mercados gubernamentales y de aviación con el cierre de la adquisición de Smith Surveying Group en Jacksonville, Florida VANCOUVER, Columbia Británica, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Florida's aviation market is experiencing substantial investments in airport expansion and modernization, which is driving demand for rapid and efficient drone-based topographic surveys and inspections, and we are ready to meet these needs

    80% confidence
  • ZenaTech's Drone as a Service, with Smith Surveying Group and A&J Land Surveyors acquisitions, is well positioned to establish a strong presence in the Jacksonville region and beyond

    80% confidence
  • This acquisition allows ZenaTech to expand its service portfolio, offering advanced drone-based data across a wide variety of applications that support sustainable development and infrastructure resilience

    80% confidence
  • Smith Surveying Group brings a long track record and trusted relationships with client communities in the Jacksonville area, and offers tremendous opportunities to deploy our Drone as a Service solutions in important verticals such as transportation, public works, utilities, commercial markets and coastal development surveying and studies

    80% confidence

Data points we hold from this source

ZenaTech, Inc. · operational start year2017 year
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com